Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RB1 | P06400 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281540 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1SMN1; SMN2HTR5ANISCH | |
| SCHEMBL2298349 | 0.79 | PTGES (0.51) | KDM4EALDH1A1MAPTGFERLMNA | |
| SCHEMBL2305408 | 0.79 | KDM4E (0.50) | KDM4EALDH1A1MAPTHTR2AHTR2C | |
| SCHEMBL13746901 | 0.79 | MAPT (0.57) | KDM4EALDH1A1MAPTHTR2AHTR2C | |
| SCHEMBL2298348 | 0.79 | PTGES (0.51) | KDM4EALDH1A1MAPTGFERLMNA | |
| SCHEMBL2305405 | 0.79 | KDM4E (0.50) | KDM4EALDH1A1MAPTHTR2AHTR2C | |
| SCHEMBL1003568 | 0.79 | MAPT (0.47) | KDM4EALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL1003566 | 0.79 | MAPT (0.47) | KDM4EALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL31603757 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2HTR5ANISCH | |
| SCHEMBL6502689 | 0.78 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2HTR5ANISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961258-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200270273-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-27 | — | — | US | disclosed |
| WO-2017109724-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| EP-1848426-B1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER FLEMING LTD (GB) | 2012-08-01 | — | — | EP | disclosed |
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | BORISOVICH FROLOV YEVGENIY (RU) | 2012-02-16 | — | — | US | disclosed |
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | BORISOVICH FROLOV YEVGENIY (RU) | 2012-02-16 | — | — | US | disclosed |
| WO-2008065408-A9 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2011-03-03 | — | — | WO | disclosed |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| WO-2008065408-A2 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HCRTR1, CDR2, MSR1 | KDM4E 4423/4885ALDH1A1 2180/4885SMN1; SMN2 61/4885 |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | KDM4E 3928/4885ALDH1A1 804/4885SMN1; SMN2 1087/4885 |
| US-10961258-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, BRAF | KDM4E 380/4885ALDH1A1 2165/4885SMN1; SMN2 4671/4885 |
| US-20200270273-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, BRAF | KDM4E 380/4885ALDH1A1 2165/4885SMN1; SMN2 4671/4885 |
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | ABCG2, HTR3C, AADAC | KDM4E 2849/4885ALDH1A1 290/4885SMN1; SMN2 3920/4885 |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | PTGES2, PTGES, PTGS2 | KDM4E 3928/4885ALDH1A1 804/4885SMN1; SMN2 1087/4885 |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HCRTR1, CDR2, MSR1 | KDM4E 4423/4885ALDH1A1 2180/4885SMN1; SMN2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.